Long-term outcomes with first- vs. second-generation drug-eluting stents in saphenous vein graft lesions

Nagendra R. Pokala, Rohan V. Menon, Siddharth M. Patel, George Christopoulos, Georgios E. Christakopoulos, Anna P. Kotsia, Bavana V. Rangan, Michele Roesle, Shuaib Abdullah, Jerrold Grodin, Dharam J. Kumbhani, Jeffrey Hastings, Subhash Banerjee, Emmanouil S. Brilakis

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background As compared with bare metal stents, first-generation drug-eluting stents (DES) improved post-procedural outcomes in aortocoronary saphenous vein graft (SVG) lesions, but there is limited information on outcomes after use of second-generation DES in SVGs. Methods We compared the outcomes of patients who received first- (n = 81) with those who received second-generation (n = 166) DES in SVG lesions at our institution between 2006 and 2013. Major adverse cardiac events (MACE) were defined as the composite of all-cause death, myocardial infarction, and target vessel revascularization. Results Mean age was 66.0 ± 8.1 years and 97.6% of the patients were men. Mean SVG age was 11.1 ± 0.4 years. First-generation DES were sirolimus-eluting (n = 17) and paclitaxel-eluting (n = 64) stents. Second-generation DES were everolimus-eluting (n = 115) and zotarolimus-eluting (n = 51) stents. Median follow-up was 41 months. At 2-years post-procedure, patients with first- and second-generation DES had similar rates of death (20.91% vs. 20.27%, P = 0.916), target lesion revascularization (16.39% vs. 20.00%, P = 0.572), target vessel revascularization (20.97% vs. 23.16%, P = 0.747), myocardial infarction (26.15% vs. 23.00%, P = 0.644), and MACE (43.5% vs. 40.87%, P = 0.707), respectively. Conclusions Outcomes with first- and second-generation DES in SVGs are similar. Novel stent designs are needed to further improve the clinical outcomes in this challenging patient and lesion subgroup.

Original languageEnglish (US)
Pages (from-to)34-40
Number of pages7
JournalCatheterization and Cardiovascular Interventions
Volume87
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Drug-Eluting Stents
Saphenous Vein
Transplants
Stents
Myocardial Infarction
Sirolimus
Paclitaxel
Cause of Death
Metals
Mortality

Keywords

  • drug eluting
  • percutaneous coronary intervention
  • saphenous vein bypass graft
  • saphenous vein graft interventions
  • stent

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Long-term outcomes with first- vs. second-generation drug-eluting stents in saphenous vein graft lesions. / Pokala, Nagendra R.; Menon, Rohan V.; Patel, Siddharth M.; Christopoulos, George; Christakopoulos, Georgios E.; Kotsia, Anna P.; Rangan, Bavana V.; Roesle, Michele; Abdullah, Shuaib; Grodin, Jerrold; Kumbhani, Dharam J.; Hastings, Jeffrey; Banerjee, Subhash; Brilakis, Emmanouil S.

In: Catheterization and Cardiovascular Interventions, Vol. 87, No. 1, 01.01.2016, p. 34-40.

Research output: Contribution to journalArticle

Pokala, Nagendra R. ; Menon, Rohan V. ; Patel, Siddharth M. ; Christopoulos, George ; Christakopoulos, Georgios E. ; Kotsia, Anna P. ; Rangan, Bavana V. ; Roesle, Michele ; Abdullah, Shuaib ; Grodin, Jerrold ; Kumbhani, Dharam J. ; Hastings, Jeffrey ; Banerjee, Subhash ; Brilakis, Emmanouil S. / Long-term outcomes with first- vs. second-generation drug-eluting stents in saphenous vein graft lesions. In: Catheterization and Cardiovascular Interventions. 2016 ; Vol. 87, No. 1. pp. 34-40.
@article{e067a77e9c67406480fc2e93699f838a,
title = "Long-term outcomes with first- vs. second-generation drug-eluting stents in saphenous vein graft lesions",
abstract = "Background As compared with bare metal stents, first-generation drug-eluting stents (DES) improved post-procedural outcomes in aortocoronary saphenous vein graft (SVG) lesions, but there is limited information on outcomes after use of second-generation DES in SVGs. Methods We compared the outcomes of patients who received first- (n = 81) with those who received second-generation (n = 166) DES in SVG lesions at our institution between 2006 and 2013. Major adverse cardiac events (MACE) were defined as the composite of all-cause death, myocardial infarction, and target vessel revascularization. Results Mean age was 66.0 ± 8.1 years and 97.6{\%} of the patients were men. Mean SVG age was 11.1 ± 0.4 years. First-generation DES were sirolimus-eluting (n = 17) and paclitaxel-eluting (n = 64) stents. Second-generation DES were everolimus-eluting (n = 115) and zotarolimus-eluting (n = 51) stents. Median follow-up was 41 months. At 2-years post-procedure, patients with first- and second-generation DES had similar rates of death (20.91{\%} vs. 20.27{\%}, P = 0.916), target lesion revascularization (16.39{\%} vs. 20.00{\%}, P = 0.572), target vessel revascularization (20.97{\%} vs. 23.16{\%}, P = 0.747), myocardial infarction (26.15{\%} vs. 23.00{\%}, P = 0.644), and MACE (43.5{\%} vs. 40.87{\%}, P = 0.707), respectively. Conclusions Outcomes with first- and second-generation DES in SVGs are similar. Novel stent designs are needed to further improve the clinical outcomes in this challenging patient and lesion subgroup.",
keywords = "drug eluting, percutaneous coronary intervention, saphenous vein bypass graft, saphenous vein graft interventions, stent",
author = "Pokala, {Nagendra R.} and Menon, {Rohan V.} and Patel, {Siddharth M.} and George Christopoulos and Christakopoulos, {Georgios E.} and Kotsia, {Anna P.} and Rangan, {Bavana V.} and Michele Roesle and Shuaib Abdullah and Jerrold Grodin and Kumbhani, {Dharam J.} and Jeffrey Hastings and Subhash Banerjee and Brilakis, {Emmanouil S.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/ccd.25982",
language = "English (US)",
volume = "87",
pages = "34--40",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Long-term outcomes with first- vs. second-generation drug-eluting stents in saphenous vein graft lesions

AU - Pokala, Nagendra R.

AU - Menon, Rohan V.

AU - Patel, Siddharth M.

AU - Christopoulos, George

AU - Christakopoulos, Georgios E.

AU - Kotsia, Anna P.

AU - Rangan, Bavana V.

AU - Roesle, Michele

AU - Abdullah, Shuaib

AU - Grodin, Jerrold

AU - Kumbhani, Dharam J.

AU - Hastings, Jeffrey

AU - Banerjee, Subhash

AU - Brilakis, Emmanouil S.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background As compared with bare metal stents, first-generation drug-eluting stents (DES) improved post-procedural outcomes in aortocoronary saphenous vein graft (SVG) lesions, but there is limited information on outcomes after use of second-generation DES in SVGs. Methods We compared the outcomes of patients who received first- (n = 81) with those who received second-generation (n = 166) DES in SVG lesions at our institution between 2006 and 2013. Major adverse cardiac events (MACE) were defined as the composite of all-cause death, myocardial infarction, and target vessel revascularization. Results Mean age was 66.0 ± 8.1 years and 97.6% of the patients were men. Mean SVG age was 11.1 ± 0.4 years. First-generation DES were sirolimus-eluting (n = 17) and paclitaxel-eluting (n = 64) stents. Second-generation DES were everolimus-eluting (n = 115) and zotarolimus-eluting (n = 51) stents. Median follow-up was 41 months. At 2-years post-procedure, patients with first- and second-generation DES had similar rates of death (20.91% vs. 20.27%, P = 0.916), target lesion revascularization (16.39% vs. 20.00%, P = 0.572), target vessel revascularization (20.97% vs. 23.16%, P = 0.747), myocardial infarction (26.15% vs. 23.00%, P = 0.644), and MACE (43.5% vs. 40.87%, P = 0.707), respectively. Conclusions Outcomes with first- and second-generation DES in SVGs are similar. Novel stent designs are needed to further improve the clinical outcomes in this challenging patient and lesion subgroup.

AB - Background As compared with bare metal stents, first-generation drug-eluting stents (DES) improved post-procedural outcomes in aortocoronary saphenous vein graft (SVG) lesions, but there is limited information on outcomes after use of second-generation DES in SVGs. Methods We compared the outcomes of patients who received first- (n = 81) with those who received second-generation (n = 166) DES in SVG lesions at our institution between 2006 and 2013. Major adverse cardiac events (MACE) were defined as the composite of all-cause death, myocardial infarction, and target vessel revascularization. Results Mean age was 66.0 ± 8.1 years and 97.6% of the patients were men. Mean SVG age was 11.1 ± 0.4 years. First-generation DES were sirolimus-eluting (n = 17) and paclitaxel-eluting (n = 64) stents. Second-generation DES were everolimus-eluting (n = 115) and zotarolimus-eluting (n = 51) stents. Median follow-up was 41 months. At 2-years post-procedure, patients with first- and second-generation DES had similar rates of death (20.91% vs. 20.27%, P = 0.916), target lesion revascularization (16.39% vs. 20.00%, P = 0.572), target vessel revascularization (20.97% vs. 23.16%, P = 0.747), myocardial infarction (26.15% vs. 23.00%, P = 0.644), and MACE (43.5% vs. 40.87%, P = 0.707), respectively. Conclusions Outcomes with first- and second-generation DES in SVGs are similar. Novel stent designs are needed to further improve the clinical outcomes in this challenging patient and lesion subgroup.

KW - drug eluting

KW - percutaneous coronary intervention

KW - saphenous vein bypass graft

KW - saphenous vein graft interventions

KW - stent

UR - http://www.scopus.com/inward/record.url?scp=84954366330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954366330&partnerID=8YFLogxK

U2 - 10.1002/ccd.25982

DO - 10.1002/ccd.25982

M3 - Article

C2 - 26033073

AN - SCOPUS:84954366330

VL - 87

SP - 34

EP - 40

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 1

ER -